COLL Collegium Pharmaceutical Inc.

Collegium to Report Second Quarter 2024 Financial Results on August 8, 2024

Collegium to Report Second Quarter 2024 Financial Results on August 8, 2024

STOUGHTON, Mass., July 25, 2024 (GLOBE NEWSWIRE) --  (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report second quarter 2024 financial results after the market closes on Thursday, August 8, 2024. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET.

Conference Call Information

To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Q2 2024 Earnings Call.” An audio webcast will be accessible from the Investors section of the Company’s website: . The webcast will be available for replay on the Company’s website approximately two hours after the event.

About Collegium Pharmaceutical, Inc.

Collegium is a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at .

Investor Contact:

Christopher James, M.D.

Vice President, Investor Relations

Media Contact:

Marissa Samuels

Vice President, Corporate Communications



EN
25/07/2024

Underlying

COLLCollegium Pharmaceutical Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Collegium Pharmaceutical Inc.

Free Trial
COLL Collegium Pharm...

Collegium Pharmaceutical Inc: 1 director

A director at Collegium Pharmaceutical Inc sold 9,593 shares at 36.623USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...

COLL COLLEGIUM PHARMACEUTICAL INC.
09/18/24 September 18, 2024 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium Completes Acquisition of Ironshore Therapeutics

Collegium Completes Acquisition of Ironshore Therapeutics – Adds Commercial Product Jornay PM®, Establishing Collegium’s Presence in Neurology (ADHD) – – Collegium Updates 2024 Financial Guidance to Reflect Expected Immediate Accretion from the Ironshore Acquisition – – 2024 Product Revenues, Net Expected in the Range of $620.0 Million to $635.0 Million – STOUGHTON, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it ...

September 4, 2024 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium to Participate in H.C. Wainwright 26th Annual Global Investm...

Collegium to Participate in H.C. Wainwright 26th Annual Global Investment Conference STOUGHTON, Mass., Aug. 30, 2024 (GLOBE NEWSWIRE) --  (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference being held in New York, NY from September 9-11, 2024. Details of the event are as follows:Fireside Chat Date and Time: Monday, September 9, 2024, at 12:30 p.m. ET T...

August 30, 2024 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium Announces Eight Poster Presentations at PAINWeek Conference ...

Collegium Announces Eight Poster Presentations at PAINWeek Conference 2024 STOUGHTON, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that eight poster presentations highlighting data regarding its diversified pain portfolio will be presented at PAINWeek Conference 2024, being held in Las Vegas, NV, from September 3–6, 2024. “Collegium is proud to present new real-world data at PAINWeek 2024 as part of our commitment to lea...

August 28, 2024 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium Reports Second Quarter 2024 Financial Results

Collegium Reports Second Quarter 2024 Financial Results – Generated Q2’24 Net Revenue of $145.3 Million and Record Belbuca® Revenue of $52.2 Million, Up 7% and 21% Year-over-Year, Respectively –        – Achieved Q2’24 GAAP Net Income of $19.6 Million, Up 51% Year-over-Year – – Delivered Q2’24 Adjusted EBITDA of $96.0 Million, Up 12% Year-over-Year – – On Track to Close Acquisition of Ironshore Therapeutics in Q3’24, Adding Commercial Product Jornay PM® to Portfolio and Establishing Presence in Neurology (ADHD) – – Reaffirmed Full-Year 2024 Guidance for the Current Business – ...

August 8, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch